Beverley Kok1, Puneeta Tandon2. 1. Division of Gastroenterology (Liver Unit), University of Alberta, 1-40 Zeidler Ledcor Building, Edmonton, Alberta, T6G 2X8, Canada. 2. Division of Gastroenterology (Liver Unit), University of Alberta, 1-40 Zeidler Ledcor Building, Edmonton, Alberta, T6G 2X8, Canada. ptandon@ualberta.ca.
Abstract
PURPOSE OF REVIEW: This review gives an overview of the evolving concept of physical frailty in patients with cirrhosis. As well as summarizing the available metrics that have been used to diagnose it, this review also examines the major recent trials that have investigated frailty in patients with cirrhosis. The complex relationship between sarcopenia and frailty is explored, and strategies to optimize frailty, such as including pharmacological and non-pharmacological therapies, are discussed. RECENT FINDINGS: Though there is heterogeneity between studies on how physical frailty in cirrhosis has been assessed, it is nonetheless becoming increasingly apparent that frailty in cirrhosis contributes to poor outcomes. A growing body of evidence strongly supports that frailty, as an entity distinct from comorbidity or measurable by laboratory-based liver disease severity, contributes to pre-transplant mortality and unplanned hospital admissions. If taken into account, frailty may improve pre-transplant mortality risk prediction. Physical frailty in cirrhosis may be objectively assessed by a number of validated metrics though at present, we lack a uniform consensus on the most appropriate tool. Early identification of frailty may allow optimization of the patient with the potential to avoiding adverse outcomes. Further studies are awaited validating and exploring optimal approaches to diagnosing and reversing frailty.
PURPOSE OF REVIEW: This review gives an overview of the evolving concept of physical frailty in patients with cirrhosis. As well as summarizing the available metrics that have been used to diagnose it, this review also examines the major recent trials that have investigated frailty in patients with cirrhosis. The complex relationship between sarcopenia and frailty is explored, and strategies to optimize frailty, such as including pharmacological and non-pharmacological therapies, are discussed. RECENT FINDINGS: Though there is heterogeneity between studies on how physical frailty in cirrhosis has been assessed, it is nonetheless becoming increasingly apparent that frailty in cirrhosis contributes to poor outcomes. A growing body of evidence strongly supports that frailty, as an entity distinct from comorbidity or measurable by laboratory-based liver disease severity, contributes to pre-transplant mortality and unplanned hospital admissions. If taken into account, frailty may improve pre-transplant mortality risk prediction. Physical frailty in cirrhosis may be objectively assessed by a number of validated metrics though at present, we lack a uniform consensus on the most appropriate tool. Early identification of frailty may allow optimization of the patient with the potential to avoiding adverse outcomes. Further studies are awaited validating and exploring optimal approaches to diagnosing and reversing frailty.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: M Plauth; E Cabré; O Riggio; M Assis-Camilo; M Pirlich; J Kondrup; P Ferenci; E Holm; S Vom Dahl; M J Müller; W Nolte Journal: Clin Nutr Date: 2006-05-16 Impact factor: 7.324
Authors: Bret H Goodpaster; Seok Won Park; Tamara B Harris; Steven B Kritchevsky; Michael Nevitt; Ann V Schwartz; Eleanor M Simonsick; Frances A Tylavsky; Marjolein Visser; Anne B Newman Journal: J Gerontol A Biol Sci Med Sci Date: 2006-10 Impact factor: 6.053
Authors: S Hirsch; D Bunout; P de la Maza; H Iturriaga; M Petermann; G Icazar; V Gattas; G Ugarte Journal: JPEN J Parenter Enteral Nutr Date: 1993 Mar-Apr Impact factor: 4.016
Authors: J L A van Vugt; S Levolger; R W F de Bruin; J van Rosmalen; H J Metselaar; J N M IJzermans Journal: Am J Transplant Date: 2016-04-04 Impact factor: 8.086
Authors: Connie W Wang; Sandy Feng; Kenneth E Covinsky; Hilary Hayssen; Li-Qin Zhou; Benjamin M Yeh; Jennifer C Lai Journal: Transplantation Date: 2016-08 Impact factor: 4.939
Authors: Bas Groot Koerkamp; Stefan Buettner; Jaynee J A Vugts; Marcia P Gaspersz; Eva Roos; Lotte C Franken; Pim B Olthof; Robert J S Coelen; Jeroen L A van Vugt; Tim A Labeur; Lieke Brouwer; Marc G H Besselink; Jan N M IJzermans; Sarwa Darwish Murad; Thomas M van Gulik; Jeroen de Jonge; Wojciech G Polak; Olivier R C Busch; Joris L Erdmann Journal: Ann Surg Oncol Date: 2020-09-08 Impact factor: 5.344